key: cord-0714722-sfq3xa5v authors: Millard, Tanya; Elliott, Julian H; Green, Sally; Tendal, Britta; Vogel, Joshua P.; Norris, Sarah; Tate, Rhiannon; Turner, Tari title: Awareness, Value and Use of the Australian living guidelines for the clinical care of people with COVID-19: An Impact Evaluation date: 2021-11-28 journal: J Clin Epidemiol DOI: 10.1016/j.jclinepi.2021.11.035 sha: 54cd5e2cb33d1ec9e7a67edcb2392f66dbbd2896 doc_id: 714722 cord_uid: sfq3xa5v INTRODUCTION: The Australian National COVID-19 Clinical Evidence Taskforce is developing living, evidence-based, national guidelines for treatment of people with COVID-19. These living guidelines are updated each week. We undertook an impact evaluation to understand the extent to which health professionals providing treatment to people with COVID 19 were aware of, valued and used the guidelines, and the factors that enabled or hampered this. METHODS: A mixed methods approach was used for the evaluation. Surveys were conducted to collect both quantitative and qualitative data and were supplemented with qualitative interviews. Australian healthcare practitioners potentially providing care to individuals with suspected or confirmed COVID-19 were invited to participate. Data were collected on guideline awareness, relevance, ease of use, trustworthiness, value, importance of updating, use, and strengths and opportunities for improvement. RESULTS: A total of 287 people completed the surveys and 10 interviews were conducted during November 2020. Awareness of the work of the Taskforce was high and the vast majority of respondents reported that the guidelines were very or extremely relevant, easy to use, trustworthy and valuable. More than 50% of respondents had used the guidelines to support their own clinical decision-making; and 30% were aware of other examples of the guidelines being used. Qualitative data revealed that amongst an overwhelming morass of evidence and opinions during the COVID-19 pandemic, the guidelines have been a reliable, united source of evidence-based advice; participants felt the guidelines built confidence and provided reassurance in clinical decision-making. Opportunities to improve awareness and accessibility to the guidelines were also explored. CONCLUSIONS: As of June 2021, the guidelines have been published and updated more than 40 times, include more than 140 recommendations and are being used to inform clinical decisions. The findings of this impact evaluation will be used to improve processes and outputs of the Taskforce and guidelines project, and to inform future living guideline projects. The Australian National COVID-19 Clinical Evidence Taskforce is developing living, evidence-based, national guidelines for treatment of people with COVID-19. These living guidelines are updated each week. We undertook an impact evaluation to understand the extent to which health professionals providing treatment to people with COVID 19 were aware of, valued and used the guidelines, and the factors that enabled or hampered this. A mixed methods approach was used for the evaluation. Surveys were conducted to collect both quantitative and qualitative data and were supplemented with qualitative interviews. Australian healthcare practitioners potentially providing care to individuals with suspected or confirmed COVID-19 were invited to participate. Data were collected on guideline awareness, relevance, ease of use, trustworthiness, value, importance of updating, use, and strengths and opportunities for improvement. A total of 287 people completed the surveys and 10 interviews were conducted during November 2020. Awareness of the work of the Taskforce was high and the vast majority of respondents reported that the guidelines were very or extremely relevant, easy to use, trustworthy and valuable. More than 50% of respondents had used the guidelines to support their own clinical decision-making; and 30% were aware of other examples of the guidelines being used. Qualitative data revealed that amongst an overwhelming morass of evidence and opinions during the COVID-19 pandemic, the guidelines have been a reliable, united source of evidence-based advice; participants felt the guidelines built confidence and provided reassurance in clinical decisionmaking. Opportunities to improve awareness and accessibility to the guidelines were also explored. Living guidelines are a new approach to developing and maintaining rigorous evidence-based guidelines in which any new, relevant evidence is rapidly incorporated, ensuring that recommendations are continually up to date with the latest research (1) . Living guideline methods are particularly useful in clinical areas in which research and practice are rapidly developing, of which COVID-19 is a clear example. A small but increasing number of living guideline projects are underway, including in stroke, diabetes, arthritis, maternal health and the recent living WHO guideline on drugs for COVID-19 (2) (3) (4) (5) , however little is currently known about the characteristics of the development or dissemination of these guidelines that make them more or less likely to succeed in having impact. The Australian National COVID-19 Clinical Evidence Taskforce is a consortium of 32 Australian health professional organisations and collaboratives representing the full range of health professionals providing care to Australians with COVID-19, co-funded by Australian national and state governments and philanthropic organisations. The Taskforce develops and maintains living guidelines for the care of people with suspected or confirmed COVID-19. The guidelines are updated each week to reflect new evidence, and the structure and methods used by the Taskforce have been described previously (6) . In brief, the guidelines use the rigorous GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach (7) and are designed to meet Australian National Health and Medical Research Council (NHMRC) standards (8) . Each week, the team identify and review new evidence; convene multiple multidisciplinary guideline panels; revise existing recommendations; and make new recommendations. The guideline recommendations are published and freely accessible via MAGIC, an online guideline platform, are disseminated widely through mainstream and social media, and are promoted widely by Taskforce member organisations (9) . The website of the National COVID-19 Clinical Evidence Taskforce (https://covid19evidence.net.au) allows users to access the living guidelines and associated clinical flowcharts. A process evaluation was conducted to explore the activity and experience of participants in the first five months of the Taskforce. The aim of the process evaluation was two-fold: to enable the Taskforce to improve process and outputs as the guideline development was underway; and to identify factors that might be useful to inform the design and development of future living guidelines (10) . Once the process evaluation was completed, and the methods and process of the living guidelines had become established, an impact evaluation was conducted to understand the extent to which clinicians were aware of, valued and used the guidelines; and the factors that underpinned this awareness, value and use. This manuscript presents the findings of the impact evaluation of the Australian living guidelines for the clinical care of people with COVID-19. An impact evaluation protocol was developed by TT, refined in discussion with the Taskforce Executive team (BT, JE, JV, RT, SN) and approved by the Taskforce Steering Committee (SG) (See appendix 1). We originally intended to interview policy makers however this was not feasible due time constraints. An expanded evaluation will commence late 2021 to capture impacts of the guidelines from policy makers. Ethics approval was provided by Monash University Human Research Ethics Committee (Project ID: 26506). A mixed-methods approach using both quantitative and qualitative data was used. Surveys were conducted to collect both quantitative and qualitative data and were supplemented by one-to-one interviews with selected participants. Two rounds of surveys were undertaken to investigate the awareness, value and use of the guidelines. The first survey was distributed on Friday July 31 2020, and remained open until Monday August 17 2020. The second survey was distributed on Friday November 19 2020, and remained open until December 9, 2020. Australian healthcare practitioners potentially providing care to individuals with suspected or confirmed COVID-19 were invited to complete these surveys. Primarily these were individual members of the 32 Taskforce member organisations. Participants were invited to complete the survey via the regular communication methods of the Taskforce and its member organisations, including but not limited to email lists, newsletters, and social media. Participation was voluntary, and completion of the online survey was considered implied consent. Data were collected using an online survey tool (Qualtrix). The survey was the same in each round. It is possible that some participants completed the survey twice. The authors were unconcerned if participants answered both surveys as all information provided was relevant to the aims of the evaluation and representative of the state of the guidelines at the respective timepoint(s). Data were collected on awareness, relevance, ease of use, trustworthiness, value, importance of updating, use, and strengths and opportunities for improvement. Both quantitative data (Likert scales, yes/no) and free text data were collected. Quantitative data were analysed using simple descriptive statistics. Qualitative data from the online surveys were combined with data collected through the interviews. Participants in the survey could also provide contact details if they wished to participate in an interview. Interview participants were invited via the regular communication methods of the Taskforce and its member organisations, including but not limited to email lists, newsletters, and social media. Potential interviewees known to the investigators were also emailed directly. Participation was voluntary and agreeing to conduct the interview was considered consent. All those who volunteered to participate were interviewed. Interview questions were based on a predetermined interview schedule, with questions varied to suit the interviewee's roles and experience. The interviews explored participants' experience of the living guidelines including how they heard about the guidelines, how they used the guidelines, strengths and weaknesses, areas for improvement (such as refining or expanding), and their judgment of the overall impact of the guidelines. Interviews were conducted via online meeting software or by phone, and were audiorecorded, de-identified and transcribed verbatim. Detailed field notes were also taken. Interviews were conducted by an experienced qualitative researcher (TT) who was not previously known to any of the interviewees. De-identified data were thematically analysed using an approach that was both inductive and deductive. Transcripts were read and re-read for familiarisation. An initial set of codes were developed by TM, and verified by TT. Some codes were identified a priori, using the interview schedule while others emerged inductively from the data. Coded extracts were collated into emerging themes which were reviewed and refined through discussion within the study team. TM undertook the primary data analysis. TT reviewed and collaborated on the conceptual development and refining of themes. A total of 287 people completed the awareness, values and use surveys. The surveys were distributed across two different time points with the intention of maximising the response rate. The first survey received 148 responses, and the second survey received 139 responses. While recommendations had been updated and new recommendations added to the guideline, no major changes had been made to the living guidelines development methods or the distribution strategy between survey rounds. An initial comparison between the results of the first and second round of the surveys revealed a high level of congruence between both the quantitative and qualitative data. As such, the data were merged and the results are presented here together. The sample included a broad range of respondents by professional role, area of clinical expertise, practice location, state and territory. At the time of this evaluation Victoria had seen the highest number of COVID-19 cases in Australia, followed by NSW which is reflected in the demographic spread of the participants. See table 1. Allied Respondents suggested many strategies to increase awareness, including increased dissemination through the member organisations, and encouraging the participants in the Guideline Panels to share on social media. Other suggestions included working closely with opinion-leaders; distributing through clinical networks, professional groups, health services, communities of practice, Australian Health Practitioner Regulation Agency (AHPRA), Australian Medical Association, and health unions; working with CEOs, senior executives and health librarians of health districts and health services; ensuring links to the guidelines are included on state and national government health websites; increasing traditional, academic and social media engagement, including podcasts; incorporating the guidelines into other decision-support tools such as 'Medical Director', 'Therapeutic Guidelines', and state guidelines; linking with clinical educators and training providers. Having a stable web address for the most recent version of the guidelines, improving the ease of download, improving findability in web searches, and developing a web/mobile app were also raised as important for building awareness. The majority of respondents reported that the guidelines were moderately (17%), very (41%) or extremely (30%) relevant to their health care practice. For most respondents who reported the guidelines were not at all or slightly (13%) or moderately relevant to their practice, this was because either they hadn't read the guidelines, or they had not seen people with COVID-19. Suggestions to improve relevance included more information on pregnancy and childbirth, and aged care, and consideration of transmission issues, infection control and the use of personal protective equipment. These topics were out of scope at the time of the evaluation. Almost all respondents reported that the guideline recommendations were moderately (31%), very (47%) or extremely (14%) easy to use. The suggestions for improving ease of use focused on improving access, and improving presentation, navigation and layout within the MAGIC platform to better emphasise key information, integrating the guidelines with related guidelines in their jurisdiction, and simplifying the flow charts to make them easy for users to adapt. Levels of trust in the guidelines were very high, with respondents reporting they were moderately (20%), very (52%) or extremely (21%) trustworthy. Issues impacting trustworthiness included a lack of primary research to include in the guideline and perceptions of inconsistency with other guidelines. Respondents emphasised that trustworthiness would be enhanced when the evidence underpinning the guidelines becomes more robust. Respondents noted that trust could be improved by increasing the visibility of care providers using the guidelines and having the guidelines endorsed by the state Chief Health Officers. Levels of use of the guideline were very high: -more than 50% of respondents had used the guidelines to support their own clinical decision-making; and 30% were aware of other examples of the guidelines being used. Respondents described having used the guidelines in a wide variety of ways, including to: inform treatment decisions for COVID-19 patients; develop local treatment guidelines and COVID-19 response strategies; compare past treatment decisions made to recommendations in the guidelines; compare with recommendations in other guidelines; seek new reliable evidence on unconventional or novel treatments; develop and deliver clinical education, and share with colleagues; explain and discuss with patients. Several respondents (30%) also reported that they were aware of others using the guidelines for purposes such as to develop or check clinic, unit, hospital, health service and state-wide guidelines, treatment pathways, protocols and policies; and to develop education programs. Frequent updating was seen as being vital to the usefulness of the guidelines, with over 90% of respondents reporting that it was very or extremely important. Respondents described the strengths of the guidelines are that they are "simple, clear, easy to follow" and "evidence based, regularly updated, clinician led". Overall, the majority of respondents thought that the guidelines were very (51%) or extremely (28%) valuable. Further data about the strengths and opportunities for improvement are presented under the qualitative evaluation. In the following presentation of the results, data from the interviews were combined with qualitative data collected through the online survey. Nine interviews were conducted with 10 interviewees during November 2020. Interview participants included medical specialists (Pharmacologist; Sleep physician; ICU consultant; ICU Registrar; Nurse educator/remote area nurse; Critical Care liaison Nurse Practitioner; Obstetrician; Public Health Nurses) who were involved in the care or guidance of care for people with COVID-19. Uncertain times: Overwhelming diversity of evidence and opinion Collectively, participants described the "early days of COVID" as being particularly stressful and overwhelming. They explained that the amount of emerging information from varied sources, along with the quantity of very diverse opinions regarding all aspects of COVID as producing a high level of uncertainty for themselves and their colleagues. Several participants were departmental heads and/or key decision makers involved in hospital care. They described feeling particularly stressed as they attempted to navigate the evidence to identify trustworthy, reliable sources to guide their clinical and policy decisions. They expressed concern that much of the emerging information at that time wasn't peer reviewed and experienced difficulties aligning views among staff members regarding important clinical decisions. Participants discussed their sense that there was a lack of common ground. They described feeling as though there was a wide variation of opinion and strategy regarding issues surrounding infection control, treatment and patient management. The overall standpoint expressed by participants was that the guidelines served as a reliable, trustworthy reference point in a time when everything was both rapidly changing and highly uncertain. They described the relief they felt when the guidelines were released and widely endorsed by contributing organisations and reputable sources. "Really, it's the one voice, the one clear voice." "We find them really useful because it's a one-stop shop for the latest evidence of where we're up to." Several factors contributed to participants' perceptions of the guidelines as being the most reliable source for evidence-based advice, including accessibility of the guidelines, the reliable 'living' process of rapidly identifying and integrating new evidence, the wide consultation methods used in developing the guidelines, and the transparent processes the guidelines employed. The group described accessibility as a major facilitator in their use of the guidelines as their preferred source for evidence-based advice. Participants recounted the different ways through which they accessed the guidelines, including keeping the homepage of MAGIC open as a browser on their phone for frequent review, relying on the weekly communiqué to alert them to updates, or accessing the guidelines via MagicApp or the Taskforce website as needed. Convenient access, clear organisation and structure were emphasised as key facilitators to their use of the guidelines as a reference point. Reliable living process Some of the participants specifically described the methods utilised by the Taskforce as key to their use of the guidelines as their preferred reference point for evidence-based advice. The daily identification and weekly integration of new evidence made the process both rigorous and highly reliable. Participants described the benefit of having the updated recommendations highlighted on both the website and in the weekly communiqué. Users reported they can quickly identify which recommendations are most relevant to them and if there have been any changes requiring changes to clinical practice. The wide consultation methods utilised through the guideline development process was repeatedly highlighted by participants as increasing the rigour of the process and thus, reinforcing their trust in the guidelines. Participants emphasised the value of having their senior colleagues, clinicians and trusted national organisations involved in the development of the guidelines as paramount to the value/trust they placed in the guidelines. They described this as critical to increasing awareness, implementation and translation of the recommendations. The importance of transparency -a clear evidence base Several participants emphasised the use of GRADE methodology as ensuring transparency of the guidelines and being key to understanding exactly why recommendations were being made for or against a particular treatment or management modality. The clarity and rigour provided by GRADE processes, particularly in describing which level of evidence was available for each recommendation facilitated enhanced trust in the guidelines. Where there was limited evidence, consensus statements were described as being extremely useful to provide guidance that was endorsed by a group of esteemed, trusted colleagues. Trust, confidence and reassurance The theme of trust ran deeply throughout the interviews. Participants emphasised the value of the guidelines in providing 'stable' reassurance that they were delivering the most current, evidencebased and peer reviewed care. They described feeling reassured knowing that the guidelines would be readily accessible should they need to access them. In a situation that commenced with an overwhelming lack of clarity and was dominated by feelings of uncertainty and being overwhelmed, participants' trust in the guidelines, and the rigorous methods the guidelines followed, translated into feelings of confidence and certainty. The guidelines were also described as a 'security blanket', not necessarily immediately required in settings of low caseload, however reassuring to have in the case of an outbreak. Complex ways through which the guidelines have had an impact In describing they ways they used the guidelines, serving as a reference point was most common. Participants explained their use of the guidelines to inform their own clinical practice, and also, from a policy and procedure point of view, where participants cross checked the recommendations of their organisation against the taskforce guidelines, aligning them as required. In discussing the future directions of the guidelines or suggested improvements, participants again emphasised the security they felt in knowing that the guidelines were current and readily accessible. Participants were satisfied with the guidelines and felt that they provided a comprehensive, useful and relevant repository of evidence and guidance. Participants were largely aware of the plans for further expansion of the guidelines. While they recognised the vital importance of keeping currency with regards to COVID-19 disease modifying treatments, participants noted that evolution of the guidelines, and potentially the model of maintaining/updating these guidelines was important. Participants expressed that the planned addition of guidance surrounding infection control, recovery and long COVID would be beneficial. "And of course now we have evolved a bit more from focusing only on treatments, now we're focusing more on the primary care aspects. And we're now getting into some of the natural history. I am starting to see some of those kinds of patients, patients who've had COVID-19 who have got ongoing issues, even though they're not infectious anymore. So I think the guidelines have definitely evolved and we're now moving into other areas, but that still doesn't take away from that initial focus, which is very much treatment focused." One of the participants suggested expanding the guidelines to provide guidance on patient education and resources to support knowledge translation. This participant noted the need for emotional support for patients and staff who are impacted or affected by COVID. This idea is connected to the sense of stress and uncertainty outlined in earlier themes. Suggestion for improving the accessibility of the guidelines were proffered including developing an app to host and access the guideline, and making the guideline in a printer friendly format. "Maybe if it was advertised as an app or had some usability features like that maybe that would mean a few more people able to use it click through it." Better integration with the guidance provided by state-level health departments was highlighted by several participants as vital to increase usability and trust in the guidelines. The need for consistent national guidance, rather than guidance which varied between states was also emphasised. Participants suggested that comparisons of the Taskforce guidance with international and state guidelines should be provided and a rationale to justify the different recommendation made in the Taskforce guidelines. "In Victoria we need to follow state guidelines, so they were helpful but not very useful for us (survey response)." "We have to follow local guidelines so couldn't follow these directly (survey response)." In mid-April 2020, the first version of the living, evidence-based Australian guidelines for the clinical care of people with COVID-19 was published including 10 recommendations. As of June 2021, the guidelines have been published and updated more 40 times and include more than 140 recommendations. At the time of the evaluation Victoria had seen the highest number of COVID-19 cases in Australia. The participants in this study described a high level of trust in the National COVID-19 evidence based clinical guidelines. They repeatedly emphasised the relief they felt that a trusted and wellsupported group were producing well informed, evidence-based clinical guidelines. In the absence of strong evidence in the earlier days of the pandemic, they emphasised the value of consensus statements being developed by experienced colleagues and organisation representatives. The transparent and reliable process utilised by the Taskforce in developing recommendations was crucial in respondents viewing the guidelines as a reliable reference point for evidence-based advice. The complex ways through which the guidelines have an impact included facilitating change in practice of individual clinicians, informing the development of clinical care pathways at state and local levels, and underpinning education activities for clinicians. The volume of research output in COVID-19 has been exponential, presenting numerous complexities to the health care system and clinicians. Over 63 000 studies have been published or registered to date, a number that increases by approximately 1000 studies per week(11). At a time of great uncertainty, the rapid development of national clinical practice guidelines has relied on consistent and trustworthy interpretation of this rapidly emerging evidence from around the world. The guidelines have provided one of the first, large-scale test cases for a living approach to GRADE-based guideline development. The success of the Australian guidelines in terms of their trustworthiness and use, highlight the value of living evidence synthesis approaches for novel diseases where the evidence base is rapidly evolving. The update schedule is significantly more frequent that other living guidelines projects (2, 3, 5) . The World Health Organization's guideline for COVID-19 drugs and the BMJ Rapid Recommendation on Remdesivir are other examples of living guidelines methods, though these guidelines are narrower in scope and updated less frequently (5) . Unlike the guidelines developed by the Taskforce, The National Institute of Health's COVID-19 Treatment Guidelines did not use GRADE "because the urgency of the pandemic required that the guideline be launched expeditiously, and there was insufficient time to train the full Panel on how to apply the GRADE framework (12) ." Limitations of this evaluation include the small number of interview participants, however the convergence of themes across the interviews and the survey results along with the diverse roles of the respondents increase our confidence in the results. Rich data were provided through the mixed-methods design. The qualitative findings were reflective of the quantitative data and provided valuable depth. The researchers in the current evaluation participated in the development of the guidelines which could have limited objectivity, however this had the benefit of increasing the depth of the understanding of the context. Ideally, the evaluation period would have been extended and results compared across time points as the living guideline methods used by the Taskforce are further refined however this was beyond the scope of this project. It was also beyond the scope of this evaluation to address the effects of the guidelines on prescribing practices or health outcomes for patients. Work by the Observation Data Working Group is underway to address these important outcomes. Finally, the findings of this study, and the feasibility and acceptability of a living guideline model such as the one used by the Taskforce may be limited in their generalisability in countries and locations that have limited access to internet. The Australian Guidelines for the Clinical Care of People with COVID-19 are an important example of intensive application of living guideline methods. The findings of this study clearly highlight the feasibility and acceptability of rapid living GRADE-based guidelines, and begin to explore how living approaches might influence the impact of guidelines. Funding to support the maintenance of living guidelines, endorsement from State and National government and integration with existing guidelines is important to the utilisation and sustainability of the living guidelines. The findings of this study provide useful insights and will be used to guide future work in this area. Specifically, the findings will be used to improve processes and outputs of the Taskforce, and to inform future living guideline projects. Work to further refine the living guideline model continues. TT and SG developed the methods, which all of the authors revised on behalf of the National COVID-19 Clinical Evidence Taskforce. TT collected the data, which TM and TT analysed. TM prepared the first draft of the manuscript and incorporated the feedback to produce the submitted version of the manuscript, which all of the authors approved. Living systematic reviews: 4. Living guideline recommendations Breathing life into Australian diabetes clinical guidelines Bringing stroke clinical guidelines to life Developing and applying a'living guidelines' approach to WHO recommendations on maternal and perinatal health A living WHO guideline on drugs for covid-19 Weekly updates of national living evidence-based guidelines: Methods for the Australian Living Guidelines for Care of People with COVID-19 GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. bmj COVID-19: What to know about the coronavirus pandemic on 6 April Making GRADE the Irresistible Choice (MAGIC) Project The Australian living guidelines for the clinical care of people with COVID-19: What worked, what didn't and why, a process evaluation Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19 Our thanks to all of the members of the National COVID-19 Clinical Evidence Taskforce for their magnificent contributions to the work described in this manuscript. TT and SG developed the methods, which all of the authors revised on behalf of the National COVID-19 Clinical Evidence Taskforce. TT collected the data, which TM and TT analysed. TM prepared the first draft of the manuscript and incorporated the feedback to produce the submitted version of the manuscript, which all of the authors approved. The National COVID-19 Clinical Evidence Taskforce is funded by the Australian Government Department of Health, the Victorian Government Department of Health and Human Services, the Ian Potter Foundation and the Walter Cottman Endowment Fund, managed by Equity Trustees, and the Lord Mayors' Charitable Foundation. The funders played no role in the development of the methods, in the writing of the report, or in the decision to submit the article for publication. The authors declare that they have no relevant conflicts of interest. Ethics approval was provided by Monash University Human Research Ethics Committee (Project ID: 24536).